Non disponible en dehors du Royaume-Uni et de l'Irlande
Application
SB-408124 was used to block orexin A-mediated cardiovascular effects in rats. It was used to study block the increase of endogenous glucose production mediated by bicuculline in rats.
Biochem/physiol Actions
SB-408124 blocks the orexin type 1 receptor that stimulates the production of stress hormone in hypothalamus. It blocks orexin A-induced increase in arterial pressure and elevation of heart rate in rats. SB-408124 modulates phrenic nerve activity that is important in respiration.
SB 408124 is an OX1 orexin receptor antagonist.
Features and Benefits
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Legal Information
Sold for research purposes under agreement from GlaxoSmithKline
Packaging
5, 25 mg in glass bottle
Ce produit répond aux critères suivants pour être admissible aux récompenses suivantes :